Biosense Webster, Inc. to Highlight Latest Innovations at AF Symposium 2023 Showcasing Breadth of Cardiac Rhythm Portfolio

Data from five company-sponsored studies across radiofrequency ablation (RFA) and pulsed field ablation (PFA) modalities will be presented

IRVINE, Calif., Jan. 23, 2023--Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,ⁱ announced that data from five company-sponsored studies, including two late breakers, will be presented at the 28^th Annual International AF Symposium in Boston from February 2–4. The studies span innovations in radiofrequency ablation (RFA) and pulsed field ablation (PFA) and are part of Biosense Webster, Inc.'s long-standing commitment to advancing electrophysiology innovation.

"With so many exciting advancements on the horizon in electrophysiology, Biosense Webster, Inc. is looking forward to connecting with our customers and partners at AF Symposium and showcasing our new, innovative solutions in cardiac arrhythmia diagnosis and treatment," said Anthony Hong, Vice President, Preclinical and Clinical Research and Medical Affairs, Cardiovascular and Specialty Solutions, Johnson & Johnson MedTech. "As a long-standing leader in this space, we are committed to harnessing the latest science and technology and working in collaboration with physicians to deliver best-in-class solutions."

Data from five Biosense Webster, Inc.-sponsored studies will be presented, spanning key topics in electrophysiology. Highlights and timing include:

• Late-breaker presentation: Paroxysmal AF Ablation Using a Novel Variable-Loop Biphasic Pulsed Field Ablation Catheter Integrated with a 3D Mapping System: One-Year Outcomes of the Multicenter inspIRE Study. Presented February 3, 5:00-6:30 p.m. EST by Dr. Vivek Reddy

This analysis is the first look at data from Biosense Webster, Inc.'s inspIRE clinical trial – a prospective, multicenter, nonrandomized study conducted in Europe to evaluate the safety and efficacy of Biosense Webster, Inc.'s investigational VARIPULSE™ Catheter and TRUPULSE™ Generator in treating symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AFib).¹

• Late-breaker presentation: Multielectrode Radiofrequency Balloon Catheter for Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation: Outcomes from the Multicenter, Worldwide STELLAR Study. Presented February 3, 5:00-6:30 p.m. EST by Dr. Sandeep Goyal

The presentation will highlight results from the STELLAR study – an FDA-regulated investigational device exemption study conducted in the US, China and Italy to assess the safety and efficacy of pulmonary vein isolation (PVI) using the HELIOSTAR™ Balloon Ablation Catheter in drug refractory symptomatic paroxysmal AFib.²

• Poster Presentation: Assessment of Optimal Dose-Response Using a Circular Pulsed Field Ablation Catheter. Presented February 2-3 in the main exhibit hall by Dr. Jonathan Hsu

The objective of this study was to assess the efficacy and safety of various PFA doses delivered intracardially using a circular catheter in a porcine model.

• Poster Presentation: Real-World Experience Comparing Zero Versus Conventional Fluoroscopy Catheter Ablation for the Treatment of Symptomatic Persistent Atrial Fibrillation. Presented February 2-3 in the main exhibit hall by Dr. Mark Metzl

This study aimed to evaluate the safety, effectiveness, and efficiency of zero-fluoroscopy symptomatic persistent atrial fibrillation ablation in a real-world setting.

• Poster Presentation: Intracardiac Echocardiography Versus Transesophageal Echocardiogram Imaging During Catheter Ablation for Atrial Fibrillation: A Multi-Hospital Retrospective Database Analysis. Presented February 2-3 in the main exhibit hall by Dr. Rhea Pimentel

This study compared healthcare use outcomes among AFib patients undergoing ablation with intracardiac echocardiography versus transesophageal echocardiogram.

Interactive In-Booth Experiences
Biosense Webster, Inc.'s exhibit booth #111 will feature opportunities for attendees to interact with the company's latest innovations, including OCTARAY™ Mapping Catheter with TRUEref™ Technology, OPTRELL™ Mapping Catheter, QDOT MICRO™ Catheter and NUVISION™ Ultrasound Catheter.

For more information about Biosense Webster Inc.'s presence at AF Symposium and the conference schedule, please visit https://www.afsymposium.com/2023-program.

About Biosense Webster, Inc.
Biosense Webster, Inc. is the global market leader in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of the Johnson & Johnson MedTech, the specialized medical-technology company is headquartered in Irvine, California, and works across the world to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care. Learn more at www.biosensewebster.com and connect on LinkedIn and Twitter.

About Johnson & Johnson MedTechⁱ
At Johnson & Johnson MedTechⁱ, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

© Biosense Webster, Inc. 2023 237340-230109

ⁱJohnson & Johnson MedTech comprises the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson's MedTech segment.
ⁱ Johnson & Johnson MedTech comprises the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson's MedTech segment.
¹ ClinicalTrials.gov. A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE) (inspire). https://clinicaltrials.gov/ct2/show/NCT04524364#contacts. Accessed January 11, 2023.
² ClinicalTrials.gov. Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR) https://clinicaltrials.gov/ct2/show/NCT03683030. Accessed January 11, 2023.